HUT61765A - Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient - Google Patents

Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient

Info

Publication number
HUT61765A
HUT61765A HU9201450A HU145090A HUT61765A HU T61765 A HUT61765 A HU T61765A HU 9201450 A HU9201450 A HU 9201450A HU 145090 A HU145090 A HU 145090A HU T61765 A HUT61765 A HU T61765A
Authority
HU
Hungary
Prior art keywords
active ingredient
pharmaceutical compositions
same
purine nucleoside
nucleoside phosphorylase
Prior art date
Application number
HU9201450A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9201450D0 (en
Inventor
John A Secrist
Mark David Erion
John A Montgomery
Steven E Ealick
Wayne C Guida
Shri Niwas
Original Assignee
Biocryst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/429,098 external-priority patent/US4985434A/en
Priority claimed from US07/429,099 external-priority patent/US5008265A/en
Priority claimed from US07/429,100 external-priority patent/US4985433A/en
Priority claimed from US07/429,097 external-priority patent/US5008270A/en
Application filed by Biocryst Inc filed Critical Biocryst Inc
Publication of HU9201450D0 publication Critical patent/HU9201450D0/hu
Publication of HUT61765A publication Critical patent/HUT61765A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/35—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU9201450A 1989-10-31 1990-10-12 Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient HUT61765A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/429,098 US4985434A (en) 1989-10-31 1989-10-31 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US07/429,099 US5008265A (en) 1989-10-31 1989-10-31 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US07/429,100 US4985433A (en) 1989-10-31 1989-10-31 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US07/429,097 US5008270A (en) 1989-10-31 1989-10-31 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US44279889A 1989-11-29 1989-11-29

Publications (2)

Publication Number Publication Date
HU9201450D0 HU9201450D0 (en) 1992-09-28
HUT61765A true HUT61765A (en) 1993-03-01

Family

ID=27541578

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9201450A HUT61765A (en) 1989-10-31 1990-10-12 Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient

Country Status (9)

Country Link
EP (1) EP0500653A4 (fr)
JP (1) JP2866478B2 (fr)
AU (1) AU654264B2 (fr)
CA (1) CA2072123C (fr)
FI (1) FI103972B1 (fr)
HU (1) HUT61765A (fr)
LV (1) LV10100B (fr)
NO (1) NO301423B1 (fr)
WO (1) WO1991006548A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
FI944933A7 (fi) * 1992-04-21 1994-10-20 Biocryst Pharm Inc 7-disubstitoitu metyyli-4-okso-3H,5H-pyrrolo(3,2-d) pyrimidiini ja sit ä sisältäviä farmaseuttisia käyttöjä ja koostumuksia
FI971413L (fi) * 1994-10-05 1997-04-04 Chiroscience Ltd Puriini- ja guaniiniyhdisteet PNP:n estäjinä
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
GB9520363D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
CN1107068C (zh) * 1997-05-29 2003-04-30 诺瓦提斯公司 2－氨基－7－(1－取代的－2－羟乙基)－3,5－二氢－吡咯并[3,2－d]嘧啶－4－酮
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
EP1539783B1 (fr) * 2002-08-21 2011-04-13 Albert Einstein College Of Medicine Of Yeshiva University Inhibiteurs des phosphorylases de nucleoside et des nucleosidases
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
CA2710039C (fr) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarnazones et composes associes, et methodes de traitement du cancer
EP2318406B1 (fr) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Composés inhibiteurs et procédés de traitement du cancer
EP2552915B1 (fr) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Composés pour le traitement du vih

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5988484A (ja) * 1982-11-09 1984-05-22 Takeda Chem Ind Ltd 新規７−デアザプリン誘導体
IE60433B1 (en) * 1986-08-26 1994-07-13 Warner Lambert Co Novel 9-deazaguanines
US4921858A (en) * 1986-10-24 1990-05-01 Warner-Lambert Company 7-deazaguanines as immunomodulators
CA1294960C (fr) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines en tant qu'immunomodulateurs
DE3726044A1 (de) * 1987-02-11 1988-08-25 Bayer Ag Akarizide mittel auf basis von azomethinderivaten und azomethine des 2,3-diaminomaleinsaeurenitrils
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
RU2093513C1 (ru) * 1989-02-27 1997-10-20 Биокрайст Фармасьютикалз Инк. Производные 9-деазагуанины или их таутомеры и фармацевтическая композиция, обладающая способностью ингибировать активность пуриннуклеозид фосфорилазы у млекопитающих
US4985433A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same

Also Published As

Publication number Publication date
NO921679D0 (no) 1992-04-29
LV10100B (en) 1995-08-20
NO301423B1 (no) 1997-10-27
JP2866478B2 (ja) 1999-03-08
FI103972B (fi) 1999-10-29
HU9201450D0 (en) 1992-09-28
FI921900A0 (fi) 1992-04-28
LV10100A (lv) 1994-05-10
CA2072123A1 (fr) 1991-05-01
FI921900L (fi) 1992-04-28
WO1991006548A1 (fr) 1991-05-16
NO921679L (no) 1992-06-17
JPH05504551A (ja) 1993-07-15
AU6712590A (en) 1991-05-31
CA2072123C (fr) 2001-06-12
AU654264B2 (en) 1994-11-03
FI103972B1 (fi) 1999-10-29
EP0500653A1 (fr) 1992-09-02
EP0500653A4 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
HUT47131A (en) Process for producing steroid-5alpha-reductase inhibitors and pharmaceutical compositions comprising them as active ingredient
HUT51222A (en) Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
IL96748A0 (en) Purine nucleoside analogues,their preparation and pharmaceutical compositions containing them
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HUT61989A (en) Process for producing 2-deoxy-2,3-didehydro-n-acetylneuraminic acid derivatives and analogs, as well as pharmaceutical compositions comprising same as active ingredient
HUT49358A (en) Process for producing phosphorous compounds, pharmaceutical compositions comprising same as active ingredient and intermediaries
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
HUT56091A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions containing them
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
HUT58060A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
HUT49625A (en) Process for producing macrolid compounds and pharmaceutical compositions comprising such active ingredient
HUT59138A (en) Process for producing carbocyclic adenosine analogs and pharmaceutical compositions comprising same as active ingredient
HUT60488A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising same
HUT51642A (en) Process for producing new 2'-halogenmethylidene, 2'-ethenylidene and 2'-ethinyl cytidine, uridine and guanosine derivatives and pharmaceutical compositions comprising same as active ingredient
HUT49367A (en) Process for producing aristeromycin/adenosine derivatives and pharmaceutical compositions comprising same as active ingredient
HUT61765A (en) Process for producing purine nucleoside phosphorylase inhibitors and pharmaceutical compositions comprising same as active ingredient
HUT54112A (en) Process for producing benzocycloalkane derivatives and pharmaceutical compositions comprising same
IL98164A0 (en) Antiviral nucleoside derivatives,process for their preparation and pharmaceutical compositions containing them
HUT54671A (en) Process for producing benzothiopirane derivatives and pharmaceutical compositions containing them as active component
IL95870A0 (en) Purine nucleoside derivatives,their preparation and pharmaceutical compositions containing them
LTIP539A (en) Inhibitors of purine nucleoside phosphorylase and process for preparing thereof
HUT54174A (en) Process for producing acylated derivatives of etoposide and pharmaceutical compositions comprising such active ingredient
HUT58736A (en) Process for producing new purine derivatives and pharmaceutical compositions containing them as active components
HUT55394A (en) Process for producing pirrolidino-piperazine-dion derivatives and pharmaceutical compositions containing them as active components
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: BIOCRYST PHARMACEUTICALS, INC., US

DFC4 Cancellation of temporary protection due to refusal